Search
for
Sort by
Research 211–240 of 1000+
- The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
- Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe
- Prescribing to save patients money: Ethical considerations
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Health Utility of Facial Angiofibroma associated with Tuberous Sclerosis Complex
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
- Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
- ALOPÉCIA COMO MANIFESTAÇÃO PÓS-COVID-19: IMPLICAÇÕES CLÍNICAS, FATORES DE RISCO E ESTRATÉGIAS FISIOTERAPÊUTICAS PARA REABILITAÇÃO CAPILAR
- Assessing the Merit of the Apple Cider Vinegar Rinse Method for Synthetic Hair Extensions
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Consider Cultural Practices and Barriers to Care When Treating Alopecia Areata
- Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Understanding the Experience of Healthcare Access and Health-Related Impacts among Individuals with Alopecia Areata
- The Incidence of Alopecia Areata in a COVID-19-Vaccinated Population: A Single-Center Review
- Platelet-Rich Plasma Applications, The Past 5 Years: A Review Article
- Treating Psoriasis: What Is New About Fumaric Acid Esters?
- Update on medical management of benign prostatic hyperplasia
- Calcineurin-based immunosuppression in renal transplantation : focus on efficacy, the role of steroids, and the cardiovascular risk
- Polycystic ovary syndrome
- Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria